Results 181 to 190 of about 15,525 (208)

Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies

Journal of the American Society for Mass Spectrometry, 2021
NK group 2 member A (NKG2A), an immune checkpoint inhibitor, is an emerging therapeutic target in immuno-oncology. NKG2A forms a heterodimer with CD94 on the cell surface of NK and a subset of T cells and recognizes the nonclassical human leukocyte antigen (HLA-E) in humans.
Richard Y.-C. Huang, Yun Wang, Amy D. Jhatakia, Andy X. Deng, Christine Bee, Shrikant Deshpande, Vangipuram S. Rangan, Natalie Bezman, Olafur Gudmundsson, Guodong Chen   +9 more
openaire   +2 more sources

The NKG2A immune checkpoint — a new direction in cancer immunotherapy

Nature Reviews Clinical Oncology, 2019
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer.
Benjamin C Creelan
exaly   +3 more sources

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board

Trends in Immunology, 2019
Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors.
Mingari, Maria Cristina, Pietra, Gabriella, Moretta, Lorenzo   +2 more
openaire   +2 more sources

CD94-NKG2A receptors regulate antiviral CD8+ T cell responses

Nature Immunology, 2002
CD8(+) T lymphocytes mediate immunosurveillance against persistent virus infections and virus-induced neoplasia. Polyoma virus, a highly oncogenic natural mouse DNA virus, establishes persistent infection, but only a few mice are highly susceptible to tumors induced by the virus.
Janice M, Moser, James, Gibbs, Peter E, Jensen, Aron E, Lukacher   +3 more
openaire   +2 more sources

Permanent silencing of NKG2A expression for cell-based therapeutics

Journal of Molecular Medicine, 2008
Natural killer (NK) and T-cell cytotoxicity is significantly reduced by signaling via CD94/NKG2A receptors. High levels of NKG2A on NK cells have been shown to compromise the graft-versus-leukemia effect in hematopoietic stem cell transplantation.
Constança, Figueiredo, Axel, Seltsam, Rainer, Blasczyk   +2 more
openaire   +2 more sources

HLA-E:CD94–NKG2A Mediates Circulating Tumor Cell Immune Evasion

Cancer Discovery, 2023
Abstract The HLA-E:CD94–NKG2A immune checkpoint mediates immune surveillance of circulating tumor cells (CTC).
openaire   +1 more source

Is CD94/NKG2A a Novel Target for Lymphoid Malignancies Immunotherapy?.

Blood, 2006
Abstract Background: Natural killer (NK)-cell receptors (NKRs) on CD8+ T cells can modulate antigen-specific T cell activity but their function and rules that govern their expression remain unclear. Among NKRs heterodimers CD94-NKG2 form either an inhibitory or an activating receptor, depending on whether CD94 associates with NKG2A or ...
Donata Urbaniak-Kujda, Jaroslaw Dybko, Iwona Prajs, Marek Kielbinski, Beata Tomaszewska-Toporska, Katarzyna Kapelko-Slowik, Kazimierz Kuliczkowski   +6 more
openaire   +2 more sources

MONOCLONAL ANTIBODIES AGAINST NKG2A

2019
The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of ...
Alessandro Moretta, Emanuela Marcenaro, Francois Romagne, Pascale Andre   +3 more
openaire   +1 more source

Abstract 2387: NKG2A-antagonizing monoclonal antibodies identified through phage display

Cancer Research, 2019
Abstract The inhibitory receptor NKG2A-CD94 is mainly expressed on NK cells and some T cell and mediates an inhibitory signal through association with a non-classical MHC class I molecule HLA-E, which is commonly over-expressed in human cancers. Targeting NKG2A with monoclonal antibody holds potentials in immunotherapy of cancer. However,
Jing Gao, Lili Hu, Ruirui Sui, Cuicui Guo, Lina Wang, Teddy Yang, Jack Han, Qing Duan, Louis Liu   +8 more
openaire   +1 more source

Molecular cloning of mouse NKG2A and C

Immunogenetics, 1999
E T, Silver, J C, Lau, K P, Kane
openaire   +2 more sources